{"id":326475,"date":"2026-10-26T11:47:46","date_gmt":"2026-10-26T06:17:46","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=326475"},"modified":"2026-10-26T11:47:46","modified_gmt":"2026-10-26T06:17:46","slug":"research-driven-contract-manufacturer-over-the-counter-formulations-exporter-and-point-of-care-molecular-diagnostics-maker-stocks-roadmap-compass-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/research-driven-contract-manufacturer-over-the-counter-formulations-exporter-and-point-of-care-molecular-diagnostics-maker-stocks-roadmap-compass-list\/","title":{"rendered":"3 Research-Driven Contract Manufacturer, Over-the-Counter Formulations Exporter and Point-of-Care Molecular Diagnostics Maker Stocks With a Strong Future Roadmap: Anthem Biosciences, Marksans Pharma and Molbio Diagnostics"},"content":{"rendered":"

Anthem Biosciences, Marksans Pharma and Molbio Diagnostics: ROE of 13.8% to 19.4% and FY22 to FY26 revenue CAGR of 15.5% to 18.6%. Prices as of 23 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

The three CDMO, OTC pharma and diagnostics stocks to watch are Anthem Biosciences, Marksans Pharma and Molbio Diagnostics. Their return on equity ranges from 13.8% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 15.5% to 18.6%. Anthem Biosciences has the highest return on equity at 19.4%, while Marksans Pharma has the fastest revenue growth at 18.6% a year. Prices are based on the 23 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n

CDMO, OTC pharma and diagnostics stocks offer a focused view of a sector where demand keeps widening. Anthem Biosciences, Marksans Pharma and Molbio Diagnostics cover a research-driven contract manufacturer, an over-the-counter formulations exporter and a point-of-care molecular diagnostics maker.<\/p>\n

This list covers three CDMO, OTC pharma and diagnostics stocks with complete current figures: Anthem Biosciences, Marksans Pharma and Molbio Diagnostics. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/a><\/strong><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n